endpts.com·Jun 8, 2026
Incyte is set to acquire Vega Therapeutics, a subsidiary of Star Therapeutics, for $1.25 billion upfront, focusing on its Phase 3 candidate for bleeding disorders.
Incyte's acquisition of Vega Therapeutics for $1.25 billion, focusing on a Phase 3 bleeding disorder candidate, highlights significant investment interest in late-stage biotech assets. This deal suggests a strong market potential for innovative treatments in niche therapeutic areas, presenting an opportunity for stakeholders in healthtech and biotech to explore similar late-stage developments for strategic partnerships or acquisitions.